BioPharma Resources

Drug Trial Radar · NCT07761117

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants With HFpEF and HFmrEF (Elevate-HF)

Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 6,950 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

6,950

Planned (sponsor's estimate)

Start

Aug 24, 2026

Primary completion

Sep 3, 2029

Study completion Sep 3, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Aug 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.

Conditions

  • Heart Failure With Preserved Ejection Fraction (HFpEF)
  • Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

Interventions

  • ElecoglipronDrug

    Elecoglipron tablet

  • PlaceboDrug

    Placebo tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of elecoglipron compared with placebo in reducing the risk of CV death or HHF/urgent HF visitTime frame: Up to 42 months

Locations

679 sites in 32 countries. Site status is shown where the registry gives one.

  • Research Site

    Fairhope, Alabama · Recruiting

  • Research Site

    Anchorage, Alaska · Not yet recruiting

  • Research Site

    Gilbert, Arizona · Not yet recruiting

  • Research Site

    Sun City, Arizona · Not yet recruiting

  • Research Site

    Beverly Hills, California · Not yet recruiting

  • Research Site

    Huntington Beach, California · Not yet recruiting

  • Research Site

    Huntington Park, California · Not yet recruiting

  • Research Site

    Loma Linda, California · Not yet recruiting

  • Research Site

    Lomita, California · Recruiting

  • Research Site

    Mather, California · Not yet recruiting

  • Research Site

    Northridge, California · Not yet recruiting

  • Research Site

    Palo Alto, California · Not yet recruiting

  • Research Site

    Redding, California · Not yet recruiting

  • Research Site

    San Diego, California · Not yet recruiting

  • Research Site

    Tarzana, California · Withdrawn

  • Research Site

    Colorado Springs, Colorado · Not yet recruiting

  • Research Site

    New Haven, Connecticut · Not yet recruiting

  • Research Site

    Bradenton, Florida · Withdrawn

  • Research Site

    Hallandale, Florida · Not yet recruiting

  • Research Site

    Jacksonville, Florida · Not yet recruiting

  • Research Site

    Lakeland, Florida · Not yet recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Miami, Florida · Not yet recruiting

  • Research Site

    Miami Lakes, Florida · Withdrawn

  • Research Site

    Miami Lakes, Florida · Recruiting

  • Research Site

    Ocala, Florida · Not yet recruiting

  • Research Site

    Ocoee, Florida · Withdrawn

  • Research Site

    Palmetto Bay, Florida · Not yet recruiting

  • Research Site

    Riverview, Florida · Not yet recruiting

  • Research Site

    Tampa, Florida · Not yet recruiting

  • Research Site

    Atlanta, Georgia · Not yet recruiting

  • Research Site

    Columbus, Georgia · Not yet recruiting

  • Research Site

    Tucker, Georgia · Not yet recruiting

  • Research Site

    Champaign, Illinois · Withdrawn

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Gurnee, Illinois · Not yet recruiting

  • Research Site

    Melrose Park, Illinois · Not yet recruiting

  • Research Site

    Moline, Illinois · Not yet recruiting

  • Research Site

    Niles, Illinois · Not yet recruiting

Showing 40 of 679 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.